News & Views
- New signups to UBook, our tailor-made NHS room booking system
- Recently launched weight management services benefit from MLCSU technology
- New flexible resourcing service: TalentOne
- Data-driven approach to population health management
- National award nomination for Staffordshire Continuing Healthcare team
- MLCSU Finance team awarded accreditation by NHS Finance Leadership Council
- Blog: My life as senior nurse on the mass vaccination programme
- Meet the director of our new service, the Transformation Unit
- Providing analytical support to the ‘New Hospitals Programme’
- MLCSU and the Transformation Unit come together
- Our year – supporting through COVID and beyond
- CIO on pandemic lessons about health inequalities in The Times report
- Equipment, software, connectivity – what it takes to digitally enable vaccination sites
- Medicines optimisation in Walsall care homes shortlisted for innovation award
- PrimaryPoint: essential IG, HR and finance support for GPs and PCNs
Improving anti-coagulant prescribing in Warrington
Our review of anti-coagulant prescribing improved patient safety and reduced costs.
Direct oral anti-coagulants (DOAC) have now increased greatly as one treatment choice over the alternative warfarin. This is because they do not require the intense monitoring needed for warfarin. Patients on a DOAC will only require more routine monitoring once a year or every three months, depending on their renal function. Risks that need to be considered with taking a DOAC include under or over coagulation and continuing treatment for longer than necessary. It is important to check that those prescribed for atrial fibrillation (AF) are correctly read-coded to be on the AF register for their practice in order to ensure correct follow up.
In each Warrington practice, our MMO team conducted a review of all patients taking any of the four DOAC medicines currently prescribed across the CCG. They looked specifically at the risk factors with DOACs. These included indication, dose and duration of therapy, as patients may remain on the incorrect dose for the indication or a longer treatment length than necessary. Duration of treatment, and stop dates for courses, were documented in patient notes. Patients’ renal function and weight was reviewed for dose prescribed and amended as appropriate.
The team checked any drug interactions and also for appropriateness of medication for indication/risk factors ensuring the clinical indication was clearly documented by read code in the GP system.
For this project, the team created bespoke searches and numerical filters to show all existing values relating to DOAC monitoring.
The DOAC review was started in March 2018 across 27 GP practices in Warrington. The table below shows the interventions that were made by the MMO team:
|Number of Patients in total from Searches on DOAC||Number of patients currently on appropriate dose (at time of audit)||Average % patients on appropriate dose||Number of patients that require missing or appropriate Read code||Number of patients that require treatment stopping or a dose reduction||Number of patients that require dose increase|
|2426||2059||85%||116 (4.8%)||114 (4.7%)||21 (0.9%)|
In addition to the safety aspect of this work there were £9,000 cost savings made in total.
Get in touch
- 1829 Building, Chester
- Old Market House
- Clark House
Countess of Chester Health Park